Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel Celyad BRU:CYAD.BL, BE0974260896

Laatste koers (eur) Verschil Volume
0,667   +0,017   (+2,62%) Dagrange 0,651 - 0,697 19.956   Gem. (3M) 70,7K

celyad 2020

3.398 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 170 »» | Laatste | Omlaag ↓
  1. Speedbul 28 mei 2020 06:57
    5 Health Care Stocks to Bet on as Coronavirus Woes Linger
    Zacks Sreoshi Bera Zacks May 27, 2020

    Celyad SA CYAD, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. By the end of May, the company is expected to report updated data from the Phase I alloSHRINK study of CYAD-101. The therapy has already shown anti-tumor activity in two out of 12 patients with a partial response in three-month duration.

    The company has an expected earnings growth rate of 0.4% for the current year. The Zacks Consensus Estimate for its current-year earnings has moved up 1.9% over the past 60 days. Celyad carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

    finance.yahoo.com/news/5-health-care-...
3.398 Posts
Pagina: «« 1 ... 107 108 109 110 111 ... 170 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.